-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

613.O4.6 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Innovations in Prognostication for Patients with Acute Myeloid Leukemia

Symposia: Acute Myeloid Leukemias: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, AML, adult, epidemiology, Clinical Practice (Health Services and Quality), Non-Biological therapies, Clinical Research, health outcomes research, Combination therapy, Chemotherapy, Diseases, Therapies, real-world evidence, Myeloid Malignancies, Study Population, Human, Minimal Residual Disease
Saturday, December 10, 2022: 9:30 AM-11:00 AM
208-210 (Ernest N. Morial Convention Center)
Moderators:
Guru Subramanian Guru Murthy, MBBS, Medical College of Wisconsin and Gina Keiffer, MD, Thomas Jefferson University
Disclosures:
No relevant conflicts of interest to declare.
This session includes studies that examine innovations in prognostication, risk factor analysis, and clinical trial design for patients with acute myeloid leukemia.
9:30 AM

Niek Van Der Maas, MSc1*, Kazem Nasserinejad, PhD1*, Thomas Pabst, MD2,3, Johan A. Maertens, MD, PhD4*, Dimitri A. Breems, MD, PhD5, Markus G Manz3,6, Jacqueline Cloos, Prof7*, Gert J. Ossenkoppele, MD, PhD8, Yngvar Floisand, MD, PhD9*, Patrycja Gradowska, MSc1*, Bob Lowenberg, MD, PhD10, Gerwin A. Huls, MD, PhD11, Douwe Postmus, PhD11*, Francesco Pignatti, MD12*, Jan J. Cornelissen, MD, PhD1 and Jurjen Versluis, MD, PhD1*

1Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands
2University Hospital Bern, Inselspital, Bern, Switzerland
3Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
4University Hospital Gasthuisberg, Leuven, Belgium
5Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium
6University Hospital Zurich, Zurich, Switzerland
7Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands
8Amsterdam Vrije Universiteit Medical Center, Amsterdam, Netherlands
9Oslo University Hospital, Oslo, Norway
10Erasmus University Medical Center, Rotterdam, Netherlands
11University Medical Center, University Groningen, Groningen, Netherlands
12Oncology and Hematology Office, European Medicines Agency, Amsterdam, Netherlands

9:45 AM

Min Yen Lo, MD1,2,3*, Cheng-Hong Tsai, MD, PhD1*, Yuan-Yeh Kuo, PhD4*, Mei-Hsuan Tseng, M.Sc.1*, Yen-Ling Peng, M.Sc.1*, Cheng-An Hsu5*, Hsun-I Sun4*, Yi-Kuang Chuang4*, Wen-Chien Chou, MD, PhD1,5, Hsin-An Hou, MD, PhD1 and Hwei-Fang Tien, MD, PhD1

1Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
2Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan
3Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
4Tai-Cheng Stem Cell Therapy Center, National Taiwan University, Taipei, Taiwan
5Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan

10:00 AM

John J. Lim, MD1*, Megan Othus, PhD2, Carole M. Shaw, BA3*, Kathryn Russell, ARNP4*, Anna B. Halpern, MD5, Jacob S. Appelbaum, MD, PhD6, Roland B. Walter, MD, PhD, MS7 and Mary-Elizabeth M. Percival, MD8

1University of Washington Medical Center, Seattle, WA
2Department of Biostatistics, University of Washington School of Public Health, Seattle, WA
3Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
4Fred Hutchinson Cancer Center, Seattle, WA
5Department of Medicine, University of Washington, Seattle, WA
6Department of Medicine, Division of Hematology, Seattle, WA
7Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
8Division of Hematology, Department of Medicine, University of Washington, Seattle, WA

10:15 AM

Hassan Awada, MD1*, Mina Abdelmalek, MD2*, Tara L. Cronin, BA3*, Jeffrey Baron, PharmD4, Zakariya Kashour, MD2*, Farhan Azad, MD2*, Muhammad Salman Faisal, MD3*, Mark G. Faber, DO5, Arya Roy, MD3*, Ashish Gupta, MD3*, Matthew Gravina, MD3*, Sheeba Ba Aqeel, MD6, Alankrita Taneja, MBBS7, Pamela J. Sung, MD3, Steven D. Green, MD3*, Amanda Przespolewski, DO6*, James E. Thompson, MD3, Elizabeth A. Griffiths, MD7 and Eunice S. Wang, MD3

1Department of Medicine, Leukemia Service,, Roswell Park Comprehensive Cancer Center, Buffalo, NY
2Department of Medicine, State University of New York at Buffalo, Buffalo, NY
3Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
4Department of Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, NY
5Department of Medicine, Leukemia Service, Roswell Park Comprehensive Cancer Center, Buffalo, NY
6Department of Hematology and Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY
7Roswell Park Comprehensive Cancer Center, Buffalo, NY

10:30 AM

Alfonso Piciocchi, MS1*, Monica Messina1*, Marta Cipriani1*, Francesca Paoloni1*, Giorgia Simonetti, PhD2*, Raffaele Palmieri, MD3*, Giovanni Marconi, MD4, Francesco Buccisano, MD3, Paola Fazi, MD1*, Marco Vignetti, MD1,5*, Giovanni Martinelli, MD6 and Adriano Venditti, MD7

1GIMEMA Foundation, Rome, Italy
2Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
3Hematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
4IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy
5Dept of Cellular Biotechnologies and Hematology, University "la Sapienza", Roma, Italy
6IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy
7Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy

10:45 AM

Metodi Balev, MD1*, Nicole Zubizarreta1*, Erin Bresnahan, MD1*, Jonathan Feld, MD1, Marina Kremyanskaya, MD, PhD1, Alla Keyzner, MD2, Alan H. Shih, MD, PhD2, Bridget K Marcellino, MD, PhD3, Lewis R. Silverman, MD2, Michal Bar-Natan, MD2, John Mascarenhas, MD1 and Douglas Tremblay, MD2

1Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
2Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
3Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

*signifies non-member of ASH